News
Opinion
Resources
Webcasts
Podcasts
White Papers
Events
E-Books
Associations and Organizations
Conferences
Conference Listing
Brand Insights
Subscribe
Advertise

logo
Spotlight
Companion Diagnostics
Digital Biomarkers
Digital Endpoints
Digital Therapeutics
Drug-Device Combinations
Medical Devices, Class II and Class III
RWE
Software as a Medical Device
Topic
AI
Clinical Care
Cybersecurity
Data Science
Remote Patient Monitoring
Payers
Strategy
News
Opinion
Webcasts
Podcasts
White Papers
Events
E-Books
Associations and Organizations
Conference Listing
Brand Insights
Subscribe
Advertise
Advertisement
AI
| Academic Research
| Clinical Care
| Clinical Trials
| Commercialization
| Companion Diagnostics
| Cybersecurity
| Data Science
| Device Development
| Digital Biomarkers
| Digital Endpoints
| Digital Therapeutics
| Drug-Device Combinations
| Ethics
| Medical Devices (Class II and Class III)
| Patient Engagement
| Payers
| Profiles/Q&A
| RWE
| Regulatory
| Remote Patient Monitoring
| SaMD
| Strategy
| Studies/Published Research
| Virtual Reality
View All >>
  • AI
  • Academic Research
  • Clinical Care
  • Clinical Trials
  • Commercialization
  • Companion Diagnostics
  • Cybersecurity
  • Data Science
  • Device Development
  • Digital Biomarkers
  • Digital Endpoints
  • Digital Therapeutics
  • Drug-Device Combinations
  • Ethics
  • Medical Devices (Class II and Class III)
  • Patient Engagement
  • Payers
  • Profiles/Q&A
  • RWE
  • Regulatory
  • Remote Patient Monitoring
  • SaMD
  • Strategy
  • Studies/Published Research
  • Virtual Reality

SPOTLIGHT -

Companion Diagnostics
| Digital Biomarkers
| Digital Endpoints
| Digital Therapeutics
| Drug-Device Combinations
| Medical Devices, Class II and Class III
| RWE
| Software as a Medical Device

Vivalink Releases Wearable ECG Patch That Can Live Stream for 14 Days

May 31, 2023
Company Press Release
Article

The patch provides real time monitoring for remote patients.

Vivalink

Vivalink
14 Day ECG Patch

Vivalink, a provider of digital healthcare solutions, announced the newest version of its multi-parameter wearable electrocardiogram (ECG) patch with continuous 14-day live stream capabilities. With Vivalink’s new patch, extended duration remote ECG monitoring can be performed with a single application of the patch, thereby reducing both clinician and patient burden. In addition, the real time streaming capabilities let clinicians remotely view a patient's live ECG anywhere anytime.

Continuous or live monitoring of ECG may be indicated for post-op care after cardiac catheterization, cardiac surgery, ablation, and cryptogenic stroke. For example, a 14-day mobile cardiac telemetry session can be performed with a single application of the patch. And at any given time, a cardiologist can view the patient’s ECG live as though the patient is in the clinic, to adjudicate events such as arrhythmias and to confirm the patient’s current status.

Continue reading this story here.

Related Videos
Related Content

Implicity Appoints Jon Hunt, PhD, As Chief Commercial Officer

September 27th 2023

FDA Releases Draft Guidance for Regulatory Considerations for Prescription Drug-Use-Related Software

September 26th 2023

FDA Approves AI Sleep Disorder Diagnosis Software

September 26th 2023

908 Devices Launches Real-Time Monitoring Platform For Multiple Bioprocess Parameters

September 22nd 2023

IceCure Medical’s ProSense System Does Not Receive Clearance for Breast Cancer

September 20th 2023

FDA Grants IDE Approval to Study of CereVasc’s eShunt System

September 19th 2023

Implicity Appoints Jon Hunt, PhD, As Chief Commercial Officer

September 27th 2023

FDA Releases Draft Guidance for Regulatory Considerations for Prescription Drug-Use-Related Software

September 26th 2023

FDA Approves AI Sleep Disorder Diagnosis Software

September 26th 2023

908 Devices Launches Real-Time Monitoring Platform For Multiple Bioprocess Parameters

September 22nd 2023

IceCure Medical’s ProSense System Does Not Receive Clearance for Breast Cancer

September 20th 2023

FDA Grants IDE Approval to Study of CereVasc’s eShunt System

September 19th 2023

Implicity Appoints Jon Hunt, PhD, As Chief Commercial Officer

September 27th 2023

FDA Releases Draft Guidance for Regulatory Considerations for Prescription Drug-Use-Related Software

September 26th 2023

FDA Approves AI Sleep Disorder Diagnosis Software

September 26th 2023

908 Devices Launches Real-Time Monitoring Platform For Multiple Bioprocess Parameters

September 22nd 2023

IceCure Medical’s ProSense System Does Not Receive Clearance for Breast Cancer

September 20th 2023

FDA Grants IDE Approval to Study of CereVasc’s eShunt System

September 19th 2023
Related Content
Advertisement
Stock.adobe.com

Implicity Appoints Jon Hunt, PhD, As Chief Commercial Officer

September 27th 2023
Articles

Hunt joins the company from HeartBeam.

stock.adobe.com

FDA Releases Draft Guidance for Regulatory Considerations for Prescription Drug-Use-Related Software

September 26th 2023
Articles

The agency differentiates between software that has a notable impact on the effectiveness and safety of drug use.

HoneyNaps

FDA Approves AI Sleep Disorder Diagnosis Software

September 26th 2023
Articles

Korean-based company HoneyNaps developed the algorithm.

908 Devices

908 Devices Launches Real-Time Monitoring Platform For Multiple Bioprocess Parameters

September 22nd 2023
Articles

The device, Maverick, utilizes Raman spectroscopy for bioprocess control.

stock.adobe.com

IceCure Medical’s ProSense System Does Not Receive Clearance for Breast Cancer

September 20th 2023
Articles

The decision will not impact the device’s FDA clearance for other indications.

FDA Grants IDE Approval to Study of CereVasc’s eShunt System

FDA Grants IDE Approval to Study of CereVasc’s eShunt System

September 19th 2023
Articles

The system will be part of a NPH study.

Mission Statement
Advertise
Editorial Information
Contact Us
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.